Xencor up on beating Q3 sales estimates

Xencor

08/11/2022 19:04

** Xencor Inc's shares  XNCR.O  rise 8.2% to $29.2 
    ** Drug developer late on Monday reported Q3 sales of $27.3
mln, beating analysts' estimates of $21 mln - Refinitiv IBES
data
    ** Co says its experimental therapy, XmAb564, to treat an
autoimmune disease, a condition in which infection fighting
cells attack healthy cell in ones body, showed promise in an
early-stage study
    ** Including session losses, stock had fallen ~27% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))